IMU · ASX

Imugene Ltd (ASX:IMU)

AU$0.42

 0.01 (2.41%)
ASX:Live
04/07/2025 04:10:02 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IMU Overview

IMU Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About IMU

Website

Imugene Ltd

Telephone

N/A

Address

Suite 12.01, Level 12 4-6 Bligh Street Sydney, New South Wales (NSW) 2000

Description

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.

IMU Price Chart

Key Stats

Market Cap

AU$95.53M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.34 - 2.75

Trade Value (12mth)

AU$189,999.00

1 week

-1.58%

1 month

-20.04%

YTD

-67.19%

1 year

-75.86%

All time high

21.25

Key Fundamentals

EPS 3 yr Growth

427.50%

EBITDA Margin

N/A

Operating Cashflow

-$97m

Free Cash Flow Return

-63.00%

ROIC

-96.90%

Interest Coverage

-282.40

Quick Ratio

3.90

Other Data

Shares on Issue (Fully Dilluted)

7408m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

5.22

IMU Announcements

Latest Announcements

Date Announcements

27 June 25

1st Patient Dosed in Australia PD1-Vaxx neo-POLEM PhII Trial

×

1st Patient Dosed in Australia PD1-Vaxx neo-POLEM PhII Trial

26 June 25

EGM Presentation

×

EGM Presentation

26 June 25

Results of Meeting

×

Results of Meeting

18 June 25

US patent allowance for onCARlytics

×

US patent allowance for onCARlytics

06 June 25

Notification of cessation of securities - IMU

×

Notification of cessation of securities - IMU

02 June 25

1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial

×

1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial

30 May 25

Dr John Byon appointed Chief Medical Officer

×

Dr John Byon appointed Chief Medical Officer

29 May 25

Consolidation/Split - IMU

×

Consolidation/Split - IMU

28 May 25

Letter to Imugene Shareholders

×

Letter to Imugene Shareholders

27 May 25

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

27 May 25

Addendum to Notice of Extraordinary General Meeting

×

Addendum to Notice of Extraordinary General Meeting

23 May 25

Notification regarding unquoted securities - IMU

×

Notification regarding unquoted securities - IMU

21 May 25

Notification of cessation of securities - IMU

×

Notification of cessation of securities - IMU

16 May 25

Proposed Consolidation of Capital

×

Proposed Consolidation of Capital

01 May 25

Letter to Shareholders

×

Letter to Shareholders

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

14 April 25

Application for quotation of securities - IMU

×

Application for quotation of securities - IMU

11 April 25

Notification regarding unquoted securities - IMU

×

Notification regarding unquoted securities - IMU

11 April 25

Notification of cessation of securities - IMU

×

Notification of cessation of securities - IMU

10 April 25

Investor Update & FAQ Webinar

×

Investor Update & FAQ Webinar

03 April 25

1st dose level cleared IV combination arm onCARlytics trial

×

1st dose level cleared IV combination arm onCARlytics trial

19 March 25

Azer-cel Granted FDA Fast Track Designation in Blood Cancer

×

Azer-cel Granted FDA Fast Track Designation in Blood Cancer

13 March 25

Application for quotation of securities - IMU

×

Application for quotation of securities - IMU

07 March 25

S&P DJI Announces March 2025 Quarterly Rebalance

×

S&P DJI Announces March 2025 Quarterly Rebalance

04 March 25

Darren Keamy Appointed CFO and Company Secretary

×

Darren Keamy Appointed CFO and Company Secretary

IMU Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.23 -0.21 -0.72 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.23 -0.21 -0.72 Lock Lock Lock
     Growth % Lock Lock Lock Lock -69.8 10.1 -249.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.15 -0.16 -0.47 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.19 0.00 -0.50 Lock Lock Lock
     Growth % Lock Lock Lock Lock -108.8 -4.2 -192.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.0 0.0 -25.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.80 1.00 0.55 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.61 0.84 0.39 Lock Lock Lock
     Growth % Lock Lock Lock Lock 197.8 37.1 -53.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 166 185 208 Lock Lock Lock
Basic m Lock Lock Lock Lock 166 185 208 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 48 49 135 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.7 8.4 -165.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -48 -49 -135 Lock Lock Lock
     Growth % Lock Lock Lock Lock -103.6 -1.7 -175.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 6 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -51 -51 -141 Lock Lock Lock
     Growth % Lock Lock Lock Lock -97.4 -1.2 -174.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -50 -50 -154 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -13 -12 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -38 -38 -150 Lock Lock Lock
     Growth % Lock Lock Lock Lock -105.2 -0.1 -294.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -31 -30 -97 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 9 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -12 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 101 83 49 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -31 0 -104 Lock Lock Lock
     Growth % Lock Lock Lock Lock -133.1 100.0 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 100 153 93 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 148 197 151 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -99 -153 -92 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 9 7 33 Lock Lock Lock
Equity $m Lock Lock Lock Lock 139 190 118 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 139 190 119 Lock Lock Lock
     Growth % Lock Lock Lock Lock 113.5 36.5 -37.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -25.7 -19.2 -98.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.3 -20.0 -126.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -49.5 -31.1 -90.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -37.1 -23.0 -96.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -30.0 -18.1 -63.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -3,554.2 -1,788.1 -282.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.1 3.1 0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -71.5 -80.5 -77.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 15.3 27.2 3.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 15.3 27.2 3.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 87.8 92.5 82.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -413.1 -489.5 -332.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -25.7 -19.2 -98.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.0 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.3 -20.0 -126.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -27.3 -20.0 -126.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 399.8 567.6 259.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -399.8 -567.6 -259.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

5.22%

Value ($M)

172

Prior Change

-0.10%

7 Day Change

0.10%

1 Month Change

N/A

3 Month Change

0.20%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMU Shortsell

Frequently Asked Questions

The current share price of Imugene Ltd (IMU:ASX) is AU$0.42.
The 52-week high share price for Imugene Ltd (IMU:ASX) is AU$2.75.
The 52-week low share price for Imugene Ltd (IMU:ASX)? is AU$0.34.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) has a franking level of 0.0%.
Imugene Ltd (IMU:ASX) is classified in the Healthcare.
The current P/E ratio for Imugene Ltd (IMU:ASX) is .
The current share price of Imugene Ltd (IMU:ASX) is AU$0.42.
The 52-week high share price for Imugene Ltd (IMU:ASX) is AU$2.75.
The 52-week low share price for Imugene Ltd (IMU:ASX)? is AU$0.34.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) has a franking level of 0.0%.
Imugene Ltd (IMU:ASX) is classified in the Healthcare.
The current P/E ratio for Imugene Ltd (IMU:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.